Abstract
The heterogeneous clinical outcome of NC AML patients (pts), who constitute about 45% of AML pts and are assigned to an intermediate-risk category, likely reflects a biologic diversity. Although mutations in FLT3, MLL, CEBPA and NPM genes and overexpression of BAALC at diagnosis can stratify prognostically NC AML, novel approaches may improve the predictive value of these markers. cDNA microarrays were used recently to gain insight into the biologic and clinical heterogeneity of NC AML. Bullinger et al. (
NEJM
2004
;350
:1605
Fig. 1A, Fig. 1B
Author notes
Corresponding author
2005, The American Society of Hematology
2005
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal